View Author
som 230 patient effect level receptor release somatostatin sst 2 adenomas adenoma secretion subtype expression culture sst 5 sst 5 receptors gh release treatment corticotroph hormone /liter study analog adenoma cells endocrinol corticotroph adenomas sst 5 mrna endocrinology acromegalic patients metab concentration inhibition control basal acth release acth release prl secretion -14 journal 20 cells gh secretion acth secretion octreotide growth prolactinoma acromegalic gh levels prl release lambert suppression srif -14 100 g oct binding tumor growth hormone sc injection medium analysis culler md cushing glucose van koetsveld pm insulin acromegaly incubation value basal gh-secreting somatostatin receptor subtypes hormone release mouse somatostatin receptors amount tissue number disease corticotroph adenoma cells crh-induced acth release ic 50 values ss -14 sst subtypes
3 Most Recent Publications
|
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
(Article)
Hofland, L.J. Hoek, J. van der Beckers, A. Lamberts, S.W.J. Feelders, R.A. Aken, M.O. van Koetsveld, P.M. van Waaijers, M. Sprij-Mooij, D. Bruns, C. Weckbecker, G. Herder, W.W. de |
2005-04-01
|
|
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
(Article)
Hoek, J. van der Poon, K.W. Uitterlinden, P. Boerlin, V. Bruns, C. Lewis, I. Lamberts, S.W.J. Weckbecker, G. Hofland, L.J. Krahnke, T. Herder, W.W. de Feelders, R.A. Lely, A.J. van der |
2004-01-01
|
|
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
(Article)
Hofland, L.J. Lely, A.J. van der Weckbecker, G. Feelders, R.A. Lamberts, S.W.J. Beckers, A. Hoek, J. van der Koetsveld, P.M. van Herder, W.W. de Waaijers, M. Sprij-Mooij, D. Bruns, C. |
2004-01-01
|
